INS and type 1 diabetes mellitus: They reported the decrement of A1C, FBS, daily insulin dose, hypoglycemic events and weight.16 Additionally, in a 4-week placebo-controlled study (EASE-1) among patients with T1D, the administration of empagliflozin for 28 days as an adjunct to insulin increased Urinary Glucose Excretion (UGE), improved A1C, and a reduced weight, significantly.